New Delhi: Ajanta Pharma BSE 2.51 % has received final approval for its generic version of acute migraine pain relief drug almotriptan malate tablets from the US health regulator.
The USFDA has so far granted final approvals for eight abbreviated new drug applications (ANDAs) and two tentative approvals, it said, adding that an additional 16 ANDAs are under review.
Latest posts by savita thakur (see all)
- 2000 medicines to become up to 90 percent cheaper: Nadda - November 7, 2016
- Drugmakers under fire for possible US price fixing - November 7, 2016
- Pharma cos see huge sell off: Sun Pharma, Dr Reddys hit hard - November 7, 2016